Physician profile
Todd A Meyer
NPI 1306863014
$4,614.76
in general payments reported to CMS, 2019-2025
12 companies · $2,449 in 2025
The $2,449 reported for 2025 was more than what 92% of Otolaryngology/Facial Plastic Surgery providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $201 · 2020: $60.63 · 2021: $1,060 · 2022: $158 · 2023: $514 · 2024: $171 · 2025: $2,449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,876 · Food and Beverage: $1,224 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,875.80 |
| Food and Beverage | $1,224.45 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $2,037.75 | 2025 | Scopis Ent |
| Inspire Medical Systems, INC. | $1,055.78 | 2021-2025 | Inspire |
| Genzyme Corporation | $421.19 | 2020-2023 | |
| Acclarent, INC | $367.16 | 2019-2023 | Trudi Nav Cable |
| Intersect Ent, INC. | $255.45 | 2019-2021 | |
| Aerin Medical INC. | $153.25 | 2025 | |
| Medtronic, INC. | $136.72 | 2023-2025 | Propel, Sinuva |
| Amgen INC. | $50.43 | 2025 | Tezspire |
| Glaxosmithkline, LLC. | $50.21 | 2023-2025 | Nucala |
| Integra Lifesciences Corporation | $49.36 | 2024-2025 | Acclarent Aera, Trudi Probe, Relieva Spinplus Nav |
| Phathom Pharmaceuticals, INC. | $21.81 | 2024 | Voquezna |
| Novartis Pharmaceuticals Corporation | $15.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.